| 영문 | androgen | 한글 | 남성호르몬, 안드로겐 |
|---|---|---|---|
| 설명 | 남성의 이차 성징을 나타내게 하는 호르몬. 테스토스테론(testosterone), 안드로스테론(androsterone) 등이 있다. |
||
| 영문 | receptor | 한글 | 수용체 |
|---|---|---|---|
| 설명 | 세포질내 또는 세포표면에 존재하는 분자구조로서 특이물질과 선택적으로 결합하며 결합에 의해 특이한 생리적 작용을 나타낸다. 펩티드호르몬, 신경전달물질, 항원, 보체, 면역글로불린에 대한 세포표면 수용체와 스테로이드에 대한 세포질내 수용체가 있다. |
||
| AR | absolute risk; accounts receivable; achievement ratio; actinic reticuloid [syndrome]; active resista... |
|---|---|
| ER | efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re... |
| RAR | rapidly adapting receptor; rat insulin receptor; retinoic acid receptor; right arm reclining; right ... |
| AIS | Androgen Insensitive Syndrome = Testicular Feminization Syndrome |
| AA | abdominal aorta; acetic acid; achievement age; active alcoholic; active assistive [range of motion];... |
| AR | Androgen Receptor |
|---|---|
| hAR | Human androgen receptor |
| AR | androgen receptor gene |
| HU-MARA | human androgen receptor |
| HU-MARA | human androgen receptor gene |
| adrenal androgen | Any androgenic hormone of adrenocortical origin; e.g., dehydroepiandrosterone (and its sulfate), androstenedione, 11b-hydroxyandrostenedione. (05 Mar 2000) |
|---|---|
| adrenal androgen-stimulating hormone | A putative pituitary hormone that may be responsible for increased secretion of adrenal androgens at the time of puberty. (05 Mar 2000) |
| androgen | <endocrinology> General term for any male sex hormone in vertebrates. Androgens may be used in patients with breast cancer to treat recurrence of the disease. (14 May 1997) |
| androgen antagonists | Compounds which inhibit or antagonise the biosynthesis or actions of androgens. (12 Dec 1998) |
| androgen binding protein | A protein secreted by testicular Sertoli cells along with inhibin and mullerian inhibiting substance. Androgen binding protein probably maintains a high concentration of androgen in the seminiferous tubules. (05 Mar 2000) |
| androgen-binding proteins | Carrier proteins produced in the sertoli cells of the testis, secreted into the seminiferous tubules, and transported via the efferent ducts to the epididymis. Participate in the transport of androgens; include also synthetic androgens binding proteins. (12 Dec 1998) |
| androgen-dependent secretory protease | <enzyme> Glycoprotein from dog prostate; hydrolyzes arginine and lysine-containing amide and ester protease substrates Registry number: EC 3.4.99.- Synonym: ads-protease (26 Jun 1999) |
| androgen resistance syndromes | A class of disorders associated with 5a-steroid reductase deficiency, testicular feminization, and related disorders. Compare: steroid 5a-reductase, Reifenstein's syndrome, infertile male syndrome, testicular feminization syndrome. (05 Mar 2000) |
| androgen unit | The androgenic activity of 100 ug (0.1 mg) of crystalline androsterone as assayed by the comb growth response in capons. (05 Mar 2000) |
| receptors, androgen | Proteins, generally found in the cytoplasm, that specifically bind androgens and mediate their cellular actions. The complex of the androgen and receptor migrates to the nucleus where it induces transcription of specific segments of DNA. (12 Dec 1998) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
| AMPA receptor | <cell biology> Glutamate operated ion channel. See: excitatory amino acid receptor channels. (05 Feb 1998) |
| ANP receptor | <molecular biology> Family of 3 receptors for atrial natriuretic peptide. ANP A and ANP B have intracellular guanylate cyclase and protein kinase like domains. ANP C, shares the extracellular ligand binding and transmembrane domains, but lacks the functional intracellular domains and is not thought to be involved in signal transduction. (18 Nov 1997) |
| asialoglycoprotein receptor | A surface receptor found in hepatocytes that binds galactose-terminal glycoproteins; thus, this receptor removes those proteins from circulation and they are in turn acted upon by hepatocyte lysosomes. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|